ABOUT US

About Us

Viewpoint Health is a boutique life sciences consultancy that was founded on the principles of using evidence, strategy and data science to maximize value and manage risk for our clients. Our deep expertise, skills, and knowledge in healthcare and life sciences along with our leading industry and academic affiliates allow us to bring focus and experience to how we manage our engagements and deliver insights and solutions to our healthcare clients.

Our focus is to provide strategy and economic consulting services to life sciences companies and law firms on a wide range of matters related to pharmaceutical access. We have assisted clients on numerous matters regarding pricing, contracting, valuation, patient services, HEOR, and operational strategy. Our Life Sciences clients include many of the largest global pharmaceutical, biotechnology and medical device manufacturers, as well as numerous early stage companies that are defining new models in the treatment and management of disease.

Our interdisciplinary staff and affiliates consist of professionals with advanced degrees in economics, statistics, public health, technology, and business. We also work closely with a network of academic experts, key opinion leaders, and physicians at leading universities who help us develop and present state-of-the-art insight and solutions for our clients. Additionally, we have an extensive network of clinical and financial decision makers across the entire healthcare value chain including payers, providers, pharmacies, PBMs, and distribution partners that provide us with deep “real-time” insight regarding critical research questions.

The Team

Debjit A. Ghosh | Founder and CEO

MBA, Columbia Business School; MA, Applied Statistics, Columbia University; MS, Public Health Policy, New York Medical College; BS, Biology, Rutgers College

Mr. Ghosh has more than 20 years of experience in health care consulting, corporate analytics, and economic analysis. He specializes in the areas of commercial strategy, pricing, contracting, and risk management. He has assisted numerous pharmaceutical, biotechnology, and medical device companies in the United States and abroad on matters of strategy and risk related to sales, marketing, pricing, and commercial operations. He has provided statistical analysis and expert support in numerous litigation matters, including analysis of damages in matters alleging off-label promotion of products, in matters alleging violation of the anti-kickback statute, and in matters related to product pricing and government reporting. He routinely assists clients on the development of strategy and models for optimizing price, value, and patient access for pharmaceutical manufacturers and also has conducted numerous complex valuation analyses for regulatory compliance and litigation matters.

Mr. Ghosh has held senior leadership positions in life sciences consulting and at Merck & Company and Pharmacia/Pfizer. He is a frequent speaker at industry conferences in the United States and abroad and is a guest lecturer at Columbia Business School.

Professor Frank R. Lichtenberg, PhD | Affiliate

BA, University of Chicago, 1973; MA University of Pennsylvania, 1976, PhD, 1982

Professor Frank Lichtenberg has been with the Columbia School of Business for 30 years, where he currently is a Courtney C. Brown Professor of Business for Finance and Economics, and a Courtney C. Brown Professor of Business for Healthcare and Pharmaceutical Management.

His research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has studied the impact of biomedical innovation on longevity and quality of life, the consequences of takeovers and LBOs for efficiency and employment, and the effect of computers on productivity in business and government organizations. A research associate of the National Bureau of Economic Research, Lichtenberg has received numerous research fellowships and grants, served as a consultant to a variety of private and public organizations and testified before Congress.

A prolific author, Professor Lichtenberg published his book, Corporate Takeovers and Productivity, and contributed the chapter Pharmaceutical Knowledge-Capital Accumulation and Longevity In Measuring Capital in the New Economy. Professor Lichtenberg’s writings have appeared a wide range of academic and industry journals such as PharmacoEconomics, International Journal of the Economics of Business, Nature Medicine and Forum for Health Economics & Policy.

Professor Lichtenberg was awarded the 1998 Schumpeter Prize for the paper “Pharmaceutical innovation as a process of creative destruction.” He was awarded the 2003 Milken Institute Award for Distinguished Economic Research for the paper “Pharmaceutical knowledge-capital accumulation and longevity,” as well as the 2010 Garfield Economic Impact Award for the publication “The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978 – 2004”.His most recent writing is the working paper The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data (Working Paper No. 19593).

Winston Wong, PharmD | Payer Insights

Dr. Wong is the President of the W-Squared Group and an affiliate of Viewpoint. Winston provides key insights to bio-pharmaceutical companies and healthcare innovators in developing their value statements and payer positioning, and then assists with developing their launch strategies in the government and commercial marketplace.

Throughout his 30-year career in the pharmacy industry, he has been repeatedly recognized for his clinical and business innovations. During his past 17 years as the Associate Vice President of Pharmacy Management at CareFirst BlueCross BlueShield, from which he retired in the fall of 2013, he was responsible for the development, implementation, and administration of the prescription benefit, including formulary development, contracting, including the Medicare Part D prescription benefit. As part of the Part D benefit, he was instrumental in the development and implementation of a pharmacist driven Medication Therapy Management (MTM) program that has been recognized by CMS, and many national organizations.

Dr. Wong also implemented one of the first successful network-based oncology treatment pathway program, a Pay-for-Quality program in which oncologists collaborated with the health plan to comply with specific treatment pathways for specific cancer types while meeting specific clinical and quality metrics. Under Dr. Wong’s leadership, the model was expanded into rheumatology and gastroenterology.

He earned his PharmD degree in 1981 from the University of the Pacific in Stockton, California, and completed a General Residency at the University of Nebraska Hospital and Clinics in Omaha, Nebraska.